US EditionHHS pharmacy sets national benchmark: First-ever delivery of groundbreaking $4.5M Hemophilia B treatment
Summary by Hospital News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
HHS pharmacy sets national benchmark: First-ever delivery of groundbreaking $4.5M Hemophilia B treatment
Hamilton Health Sciences (HHS) outpatient pharmacy recently made history by becoming the first in Canada to receive a delivery of Hemgenix, a $4.5 million, one-time gene therapy for adults with Hemophilia B, a rare genetic bleeding disorder. The delivery to the outpatient pharmacy at HHS McMaster University Medical Centre (MUMC) involved following a wide range of protocols for receiving and storing this highly valuable drug, and underscores the …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
